Impact of the time to achieve viral control on the dynamics of circulating HIV-1 reservoir in vertically infected children with long-term sustained virological suppression: A longitudinal study

PLoS One. 2018 Oct 23;13(10):e0205579. doi: 10.1371/journal.pone.0205579. eCollection 2018.

Abstract

Objective: Determine the decay rate of HIV-1 DNA reservoir in vertically infected children during sustained viral suppression (VS) and how it is affected by the age at VS.

Methods: This study included 37 HIV-1 vertically infected children on suppressive antiretroviral therapy for at least 4 years. Children were grouped according to the age of antiretroviral therapy initiation (≤0.5 or >0.5 yrs) and to the age at VS (≤1.5, between >1.5 and 4, and >4 years). Decay of cell-associated HIV-1 DNA (CA-HIV-DNA) level and 2-long terminal repeats (2-LTR) circles frequency were analyzed over 4 years of viral suppression using piecewise linear mixed-effects model with two splines and logistic regression, respectively.

Results: CA-HIV-DNA in peripheral blood mononuclear cells had a significant decay during the first two years of VS [-0.26 (95% CI: -0.43, -0.09) log10 copies per one million cells (cpm)/year], and subsequently reached a plateau [-0.06 (95% CI: -0.15, 0.55) log10 cpm/year]. The initial decay was higher in children who achieved VS by 1.5 years of age compared to those who achieved VS between >1.5 and 4 years and those after 4 years of age: -0.51 (95% CI:-0.94, -0.07), -0.35 (95% CI:-0.83, 0.14), and -0.21 (95% CI:-0.39, -0.02) log10cpm PBMC/year, respectively. The 2-LTR circles frequency decayed significantly, from 82.9% at pre-VS to 37.5% and 28.1% at 2 and 4 years of VS, respectively (P = .0009).

Conclusions: These data highlight that achieving VS during the first 18 months of life limit the establishment of HIV-1 reservoirs, reinforcing the clinical benefit of very early effective therapy in children.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Cohort Studies
  • DNA, Viral / blood*
  • Female
  • HIV Infections / blood*
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV-1* / genetics
  • Humans
  • Infant
  • Leukocytes, Mononuclear / drug effects
  • Leukocytes, Mononuclear / virology
  • Longitudinal Studies
  • Male
  • Sustained Virologic Response
  • Time-to-Treatment
  • Viremia / blood
  • Viremia / drug therapy
  • Viremia / immunology

Substances

  • Anti-HIV Agents
  • DNA, Viral

Grants and funding

This work was supported by Fondo Nacional para Ciencia y Tecnología (FONCYT) [grant number PICT 2014-1373], http://www.agencia.mincyt.gob.ar/foncyt.php. DM was a recipient of a fellowship from Fundación Garrahan, Dirección Asociada de Docencia e Investigación Hospital de Pediatría ‘Prof. Dr Juan P. Garrahan’, http://www.garrahan.gov.ar/. PA and AM are researchers from CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas), Buenos Aires, Argentina. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.